ClinicalTrials.gg
RecruitingNCT05914116Updated Oct 21, 2026

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

A Phase 1/2 interventional study of DB-1311 and Lopinavir and Ritonavir Tablets in Advanced Solid Tumors, sponsored by DualityBio Inc.. Recruiting at 107 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by DualityBio Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.
Updated Oct 21, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
862
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 365 studies in Small Cell Lung Carcinoma with a site in China — 183 open to participants now, 215 under way, 36 of them phase 3. Small Cell Lung Carcinoma · China.

Planned enrollment
8th of 333
862 · median 63
Started
2023
with 36 others
Phase 1/2
42 of 365
30 open now
Primary completion
2027-12
later than 133 of 214 live
Registered
183rd of 365
by date

Among the 365 studies in Small Cell Lung Carcinoma with a site in China, this one is the 8th largest by planned enrollment of the 333 interventional ones that give a count, is one of 37 that started in 2023, is one of 42 in phase 1/2, reaches primary completion later than 133 of the 214 other live ones, and was the 183rd registered.

Small Cell Lung Carcinoma

1,302 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

183 of the 365 studies in Small Cell Lung Carcinoma with a site in China are open now. Recruiting first, the newest first:

178 more — sign in →

All 183 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Small Cell Lung Carcinoma with a site in China, or all of them as a file.
02

Study summary

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

Read the detailed description

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a study. Phase 1 adopts an accelerated titration at first dose level followed with classic "3+3" design to identify the MTD (maximum tolerated dose) and/or RP2D(Recommended Phase 2 Dose). Phase 2a is a dose expansion phase to confirm the safety, tolerability and explore efficacy in selected malignant solid tumors treated with DB-1311/BNT324 as monotherapy or in combination with novel hormone therapy (NHT) in prostate cancer (PC). And the drug-drug-interaction (DDI) sub-study to evaluate the effect of lopinavir/ritonavir and itraconazole on the PK of DB-1311 and its payload.

03

Conditions studied

  • Advanced Solid Tumors

Keywords

  • B7-H3
  • SCLC (small cell lung cancer)
  • NSCLC (non-small cell lung cancer)
  • ESCC (esophageal squamous cell carcinoma)
  • CRPC (castration-resistant prostate cancer)
  • Melanoma
  • HCC (Hepatocellular Carcinoma)
  • HNSCC (Head and neck squamous cell carcinomas)
  • CC (Cervical Cancer)
  • PROC (platinum-resistant ovarian cancer)
  • PC (prostate cancer)
  • CSPC (castration-sensitive prostate cancer)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female adults (defined as ≥ 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of ).
  2. or cytologically confirmed unresectable advanced/ solid tumor that has or progressed on or after standard systemic treatments, or is intolerable with standard treatment; or for which no standard treatment is available.
  3. At least one as assessed by the investigator according to (RECIST) version 1.1 criteria (measurable disease as defined by RANO 2.0 criteria for GBM subjects). Castrate-resistant prostate cancer (CRPC) subjects with bone only disease may be eligible on a case-by- case basis after discussion with the Medical Monitor.
  4. Has a of ≥ 3 months.
  5. Has an (ECOG) performance status (PS) of 0-1.
  6. Has ≥ 50% by either echocardiography (ECHO) or multiple-gated acquisition (MUGA) within 28 days before enrollment.
  7. Has adequate organ function within 7 days prior to Day 1 of Cycle 1
  8. Has adequate treatment prior to Day 1 of Cycle 1
  9. Is willing to provide pre-existing resected tumor samples or undergo fresh tumor for the measurement of B7-H3 level and other biomarkers if no .

    Note: there is no minimum B7-H3 expression level mandatory for entry into the study.

  10. Is capable of comprehending study procedures and risks outlined in the informed consent and able to provide written consent and agree to comply with the requirements of the study and the schedule of assessments.
  11. Male and female subjects of reproductive/ must agree to use adequate methods (e.g., double barrier or intrauterine contraceptive) during the study and for at least 4 months and 7 months after the last dose of study drug, respectively.
  12. Male subjects must not freeze or donate sperm starting at screening and throughout the study period, and at least 4 months after the final study drug administration.
  13. Female subjects must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the final study drug administration.
  14. SCLC subjects (Phase 2a Cohort 1 ONLY):

    • Pathologically documented locally advanced, or metastatic SCLC not amenable to curative surgery or radiation.
    • Prior therapy with at least one platinum-based line as systemic therapy for extensive stage disease with at least two cycles of therapy (except in the case of early objective PD).
    • Prior treatment regimens with irinotecan, topotecan or any other TOP I inhibitor including TOP I inhibitors are not allowed.
  15. NSCLC subjects (Phase 2a Cohort 2 ONLY):

    • Pathologically documented locally advanced, or metastatic NSCLC and is not amenable to curative surgery or radiation.
    • Has received prior treatment with platinum-based chemotherapy regimen and/or /PD-L1 antibody-based regimen in the advanced/unresectable, or metastatic setting unless unable or unwilling. Subjects with NSCLC known to harbor a genomic alteration(s) other than EGFR mutation(s) (e.g., ALK rearrangement, ROS1 rearrangement, KRAS G12C mutation, BRAF V600E mutation, NTRK1/2/3 Gene fusion, MET Exon 14 skipping, RET rearrangement etc.) for which treatment is available must have also received prior treatment with at least 1 genotype-directed therapy.
  16. ESCC subjects (Phase 2a Cohort 3 ONLY):

    • Pathologically documented locally advanced, or metastatic ESCC and is not amenable to curative surgery or radiation.
    • Having received at least one prior therapy for unresectable disease. Patients with recurrence within 6 months of completion of or adjuvant therapy will be considered as having received one prior therapy for unresectable disease.
  17. CRPC subjects (Phase 2a Cohort 4 ONLY):

    • Pathologically documented metastatic adenocarcinoma of the prostate cancer.
    • Progressive metastatic CRPC as defined: 1) castrate levels of serum testosterone \< 50 ng/dL AND 2) progressive disease as defined by PCWG3 criteria.
    • Having received prior docetaxel (before or after an AR-targeted therapy). Docetaxel rechallenge was allowed.
    • Having received prior novel hormone therapy.
  18. Melanoma subjects (Phase 2a Cohort 5 ONLY) • Histologically or cytologically confirmed diagnosis of unresectable Stage III or metastatic melanoma not amenable to local therapy, must have had either:

    > Previously treated with a PD-1 or PD-L1 inhibitor.

    > If subjects with BRAF gene mutant melanoma, must have had a prior treatment regimen that included vemurafenib, dabrafenib, or another BRAF gene and/or mitogen-activated protein kinase (MEK) protein inhibitor.

  19. HCC subjects (Phase 2a Cohort 6 ONLY)

    • Histological/cytological confirmed diagnosis of HCC or clinically confirmed diagnosis of HCC as per American Association for the Study of Liver Diseases (AASLD) criteria (fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC are not eligible), and:
    • Has received 1 or 2 prior systemic therapy regimens for recurrent or metastatic disease;
    • Has experienced disease progression during or after treatment with an anti-PD-1/L1 agent administered either as monotherapy or in combination.

    Note: Subjects basically should receive prior standard therapy.

    • However, if the investigator judges the therapy is not appropriate for the subject, the prior standard therapy is not necessarily mandated for the eligibility.
    • Has a class A liver score within 7 days of first dose of study drug.
  20. Cervical cancer subjects (Phase 2a Cohort 7 ONLY) • Has recurrent or metastatic cervical cancer with squamous cell, adenocarcinoma, or adenosquamous histology, and:

    • Has experienced disease progression during or after treatment with a standard of care systemic chemotherapy doublet, or platinum-based therapy (if eligible), defined as either: d. paclitaxel + cisplatin + bevacizumab + anti-PD-(L)1 agent, or e. paclitaxel + carboplatin + bevacizumab + anti-PD-(L)1 agent, or f. paclitaxel + topotecan + bevacizumab + anti-PD-(L)1 agent Note: In cases where bevacizumab and/or anti-PD-(L)1 agent is not a standard of care therapy or the subject was ineligible for such treatment according to local standards, prior treatment with bevacizumab and/or anti-PD-(L)1 agent is not required.
    • Has received 1 or 2 prior systemic therapy regimens for recurrent or metastatic cervical cancer. Chemotherapy administered in the adjuvant or neoadjuvant setting, or in combination with radiation therapy, should not be counted as a systemic therapy regimen. Single agent therapy with an anti-PD(L)1 agent for recurrent or metastatic cervical cancer should be counted.
  21. Subjects with other solid tumors (Phase 2a Cohort 8 ONLY) • Histologically or cytologically confirmed solid tumors. • Progressed or relapsed after at least one prior standard therapeutic regimen (Patients who have not received all approved or standard treatments for their cancer must be informed that these alternatives to receiving DB-1311/BNT324 are available prior to consenting to participate in this trial).
  22. HNSCC subjects (Phase 2a Cohort 9 and Cohort 13)

    • Histologically or cytologically confirmed refractory/metastatic (R/M) HNSCC (not including NPC) that is considered incurable by local therapies.
    • Progressed on or after prior standard therapeutic regimen.
  23. Subjects with rare tumors (Phase 2a Cohort 10 ONLY) Histologically or cytologically confirmed rare tumor types. Progressed or relapsed after at least one prior standard therapeutic regimen (Patients who have not received all approved or standard treatments for their cancer must be informed that these alternatives to receiving DB-1311/BNT324 are available prior to consenting to participate in this trial).
  24. Post lutetium-177 CRPC subjects (Phase 2a Cohort 11 ONLY):

    Pathologically documented metastatic adenocarcinoma of the prostate cancer. Progressive metastatic CRPC as defined: 1) castrate levels of serum testosterone \< 50 ng/dL AND 2) progressive disease as defined by PCWG3 criteria.

  25. Taxane-naive CRPC subjects (Phase 2a Cohort 12, 16, 17 ONLY)

    • Pathologically documented metastatic adenocarcinoma of the prostate cancer. Progressive metastatic CRPC as defined: 1) castrate levels of serum testosterone \< 50 ng/dL AND 2) progressive disease as defined by PCWG3 criteria.

      26, PROC subjects (Phase 2a Cohort 14 ONLY)

    • Subjects must have a confirmed diagnosis of OC, primary peritoneal cancer, or fallopian tube cancer, all of which with high-grade serous or endometrioid histology..
    • Subjects must have platinum-resistant disease:
    • Received at least 1 but ≤ 3 lines of prior systemic anticancer therapy and have radiographic progressed on or after their most recent .

27. CSPC with suboptimal PSA response (Phase 2a Cohort 18 ONLY)

  • Pathologically documented adenocarcinoma of the prostate cancer.
  • Having advanced/unresectable, or metastatic disease and confirmed by imaging (e.g., CT and/or bone scan).
  • Having received ADT and enzalutamide or abiraterone for ≥4 months, with suboptimal PSA response.

    28. Additional inclusion criteria for DDI cohort: has a study treatment expectancy of >= 2.5 months. Able to withhold /P-gp/OATP1B inhibitors or substrates or CYP3A inducers as concomitant treatments for certain period.

Exclusion criteria

Exclusion Criteria:

Unless otherwise specified, the exclusion criteria are common to both Phase 1 and Phase 2a. Subjects who meet any of the following criteria will be excluded from the study:

  1. Prior treatment with B7-H3 targeted therapy.
  2. Prior treatment with antibody drug conjugate with topoisomerase inhibitor (e.g., trastuzumab deruxtecan).
  3. Has a medical history of symptomatic congestive heart failure (CHF) ( [NYHA] classes II-IV) or serious cardiac arrhythmia requiring treatment.
  4. Has a medical history of myocardial infarction or unstable angina within 6 months before enrollment.
  5. Has an average of Fredericia's formula- corrected interval (QTcF) prolongation to > 470 millisecond (ms) in males and females based on a 12-lead (ECG) in triplicate.
  6. Use of concomitant medications known to prolong the QT interval. If the use is deemed necessary, they should be administered with caution and closely monitoring the QT interval, after discussed with the Sponsor.
  7. Has a medical history of interstitial lung diseases (e.g., non-infectious interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening.
  8. Has a history of underlying pulmonary disorder including, but not limited to, pulmonary emboli within 3 months of the start of study treatment, severe asthma, severe , restrictive lung disease, and other pulmonary compromise or requirement for supplemental oxygen.
  9. Clinically significant gastrointestinal disorder including, but not limited to, history of gastrointestinal fistulation that need long-term intravenous nutrition; gastrointestinal dysfunction that need long-term enteral nutrition through the tube feeding; gastrointestinal obstruction/perforation that not recovered within 6 months prior to the enrollment.
  10. Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk of bleeding; A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment (Only applicable to HCC patients).
  11. disease that involves major airways or blood vessels (e.g., patients with vascular invasion of the major portal vein and inferior vena cava).
  12. Clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring drainage, peritoneal shunt or cell-free concentrated ascites reinfusion therapy within 2 weeks prior to the enrollment.
  13. Any , connective tissue or inflammatory disorders (e.g., rheumatoid arthritis, Sjögren's, sarcoidosis) where there is documented, or a suspicion of pulmonary involvement at the time of screening.
  14. Has an uncontrolled infection requiring intravenous injection of antibiotics, antivirals, or antifungals.
  15. Know (HIV) infection.
  16. Subjects have active viral (any etiology) hepatitis are excluded. However, subjects with serologic evidence of chronic virus (HBV) infection (defined by a positive hepatitis B surface antigen [HBsAg] test or a positive hepatitis B core antibody test) who have a viral load below the limit quantification (e.g., HBV DNA titer \< 1000 cps/mL or 200 IU/mL) and are willing to and maintain antiviral treatment if required, are eligible. However, subjects with a history of virus (HCV) infection who have completed curative antiviral treatment and have a viral load below the limit of quantification are eligible for study entry.
  17. Is a lactating mother (women who are willing to temporarily interrupt breastfeeding will also be excluded), or pregnant as confirmed by pregnancy tests performed within 7 days prior to enrollment.
  18. Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with or anticonvulsants to control associated symptoms. Subjects with clinically inactive may be included in the study. Subjects with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and study randomization.
  19. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to version 5.0, grade ≤ 1 or baseline. Subjects with chronic Grade 2 toxicities (e.g., Grade 2 neuropathy) may be eligible based on the discussion and agreement between Investigator and Sponsor.
  20. Has multiple primary within 3 years before enrollment, except adequately resected non-melanoma skin cancer (e.g., resected basal or squamous cell skin cancer), curatively treated in-situ disease (e.g., carcinoma in situ of the cervix or breast), other solid tumors curatively treated (e.g., superficial bladder cancer), or contralateral breast cancer.
  21. Has substance abuse or any other medical conditions that would increase the safety risk to the subject or interfere with participation or evaluation of the clinical study in the opinion of the investigator.
  22. Has known to either the drug substances or inactive ingredients in the drug product.
  23. Patients with other reasons that, in the opinion of the Investigator, make them unsuitable to participate in this study.
  24. Additional exclusion criteria for DDI cohort: Has a for receiving lopinavir, ritonavir or itraconazole according to the prescribing information is not able to take lopinavir, ritonavir or itraconazole by oral intake.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
862 participants (estimated)

Study arms

  • Experimental
    DB-1311/BNT324 Dose Level 1

    Enrolled Subjects will receive a single-dose of DB-1311/BNT324 at Dose Level 1 on Day 1 of each cycle Q3W (every 3 weeks)

    Drug: DB-1311

  • Experimental
    DB-1311/BNT324 Dose Level 2

    Enrolled Subjects will receive a single-dose of DB-1311/BNT324 at Dose Level 2 on Day 1 of each cycle Q3W

    Drug: DB-1311

  • Experimental
    DB-1311/BNT324 Dose Level 3

    Enrolled Subjects will receive a single-dose of DB-1311/BNT324 at Dose Level 3 on Day 1 of each cycle Q3W

    Drug: DB-1311

  • Experimental
    DB-1311/BNT324 Dose Level 4

    Enrolled Subjects will receive a single-dose of DB-1311/BNT324 at Dose Level 4 on Day 1 of each cycle Q3W

    Drug: DB-1311

  • Experimental
    DB-1311/BNT324 Dose Level 5

    Enrolled Subjects will receive a single-dose of DB-1311/BNT324 at Dose Level 5 on Day 1 of each cycle Q3W

    Drug: DB-1311

  • Experimental
    DB-1311/BNT324 Dose Expansion 1

    Subjects with advanced/unresectable, or metastatic SCLC who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324 randomized at dose level 1 or 2.

    Drug: DB-1311

  • Experimental
    DB-1311/BNT324 Dose Expansion 2

    Subjects with advanced/unresectable, or metastatic NSCLC who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324 randomized at dose level 1 or 2.

    Drug: DB-1311

  • Experimental
    DB-1311/BNT324 Dose Expansion 3

    Subjects with advanced/unresectable, or metastatic ESCC who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.

    Drug: DB-1311

  • Experimental
    DB-1311/BNT324 Dose Expansion 4

    Subjects with advanced/unresectable, or metastatic CRPC who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324 randomized at dose level 1 or 2.

    Drug: DB-1311

  • Experimental
    DB-1311/BNT324 Dose Expansion 5

    Subjects with advanced/unresectable, or metastatic melanoma who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.

    Drug: DB-1311

  • Experimental
    DB-1311/BNT324 Dose Expansion 6

    Subjects with advanced/unresectable, or metastatic HCC who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.

    Drug: DB-1311

  • Experimental
    DB-1311/BNT324 Dose Expansion 7

    Subjects with advanced/unresectable, or metastatic cervical cancer who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.

    Drug: DB-1311

  • Experimental
    DB-1311/BNT324 Dose Expansion 8

    Subjects with other advanced or metastatic solid tumors who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.

    Drug: DB-1311

  • Experimental
    DB-1311/BNT324 Dose Expansion 9

    Subjects with advanced/unresectable, or metastatic HNSCC (not including nasopharyngeal carcinoma \[NPC\]) who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.

    Drug: DB-1311

  • Experimental
    DB-1311/BNT324 Dose Expansion 10

    Subjects with advanced or metastatic rare tumor types who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.

    Drug: DB-1311

  • Experimental
    DB-1311/BNT324 Dose Expansion 11

    Subjects with metastatic CRPC who have progressed on or after standard systemic treatments including no more than 2 lines of systemic chemotherapy, novel hormone therapy and lutetium-177 radioligand therapy, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.

    Drug: DB-1311

  • Experimental
    DB-1311/BNT324 Dose Expansion 12

    Taxane-naive subjects with metastatic CRPC who have progressed on or after novel hormone therapy, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.

    Drug: DB-1311

  • Experimental
    DB-1311/BNT324 Dose Expansion 13

    Subjects with advanced/unresectable, or metastatic HNSCC (not including NPC) who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324.

    Drug: DB-1311

  • Experimental
    DB-1311/BNT324 Dose Expansion 14

    Subjects with epithelial OC who have had 1-3 prior lines of systemic treatment and are platinum-resistant, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324 randomized at dose level 1 or 2.

    Drug: DB-1311

  • Experimental
    DB-1311/BNT324 Dose Expansion 15

    Subjects with Subjects with advanced/unresectable, or metastatic melanoma, ESCC, PROC and CC who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via IV will be used for DB-1311/BNT324. Lopinavir and ritonavir/ Itraconazole will be administered orally twice a day/ once a day.

    Drug: DB-1311 · Drug: Lopinavir and Ritonavir Tablets · Drug: itraconazole

  • Experimental
    DB-1311/BNT324 Dose Expansion 16

    Taxane-naive subjects with metastatic CRPC who have progressed on or after NHT, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324, combined with enzalutamide 160mg QD orally.

    Drug: DB-1311 · Drug: Enzalutamide

  • Experimental
    DB-1311/BNT324 Dose Expansion 17

    Taxane-naive subjects with metastatic CRPC who have progressed on or after NHT, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324, combined with abiraterone 1000mg QD orally.

    Drug: DB-1311 · Drug: Abiraterone

  • Experimental
    DB-1311/BNT324 Dose Expansion 18

    CSPC subjects with suboptimal PSA response to ADT/NHT, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311/BNT324, combined with enzalutamide 160mg or abiraterone 1000mg QD orally.

    Drug: DB-1311 · Drug: Enzalutamide · Drug: Abiraterone

Interventions

  • Administered I.V.(intravenous infusion)

  • DrugLopinavir and Ritonavir Tablets

    Lopinavir and Ritonavir Tablets

  • itraconazole

  • oral administration

  • oral administration

06

What researchers measure

Primary outcomes

  1. Phase 1: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Percentage of participants in Part 1 with DLTs

    Percentage of participants in Part 1 with DLTs

    Time frame: up to 21 days after Cycle 1 Day 1

  2. Phase 1& Phase 2a: Percentage of Participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE v5.0.

    Percentage of participants with TEAEs graded according to National Cancer Institute (NCI) CTCAE v5.0

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  3. Phase 1& Phase 2a: Percentage of Participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.

    Percentage of Participants with SAEs graded according to NCI CTCAE v5.0

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  4. Phase 1 & Phase 2a: vital sign measurements

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  5. Phase 1& Phase 2a: clinical safety laboratory parameters

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  6. Phase 1& Phase 2a: Electrocardiogram (ECG) parameters

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  7. Phase 1& Phase 2a: Eastern Cooperative Oncology Group (ECOG) performance status (PS)

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  8. Phase 1& Phase 2a: left ventricular ejection fraction (LEVF)

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  9. Phase 1: Maximum Tolerated Dose (MTD) of DB-1311/BNT324

    MTD on the data collected during Part 1

    Time frame: Up to the completion of Part 1 (assessed up to 12 months)

  10. Phase 1: Recommended Phase 2 Dose (RP2D) of DB-1311/BNT324

    RP2D of DB-1311/BNT324 based on the data collected during Part 1

    Time frame: Up to the completion of Part 1 (assessed up to 12 months)

  11. Phase 2a: Objective Response Rate (ORR) as determined by investigator

    Objective Response Rate (ORR) as determined by investigator per RECIST 1.1 in non-PC/non-GBM participants per RECIST v1.1 for soft tissue and Prostate Cancer Working Group 3 (PCWG3) criteria for bone metastases in PC participants, and ORR per neuro-oncology 2.0 (RANO 2.0) criteria in GBM participants.

    Time frame: Up to follow-up period, approximately 1 year post-treatment

Secondary outcomes

  1. Phase 1: Objective response rate (ORR)

    ORR will be determined by investigator per RECIST v1.1 in non-CRPC participants, and per RECIST v1.1 for soft tissue and PCWG3 criteria for bone metastases in CRPC participants

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  2. Phase 1 & Phase 2a: duration of response (DoR)

    DoR will be determined by investigator per RECIST v1.1 in non-PC/non-GBM participants, per RECIST v1.1 for soft tissue and PCWG3 criteria for bone metastases in PC participants, and per RANO 2.0 criteria in GBM participants

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  3. Phase 1 & Phase 2a: disease-control rate (DCR)

    DCR will be determined by investigator per RECIST v1.1 in non-PC/non-GBM participants, per RECIST v1.1 for soft tissue and PCWG3 criteria for bone metastases in PC participants, and per RANO 2.0 criteria in GBM participants

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  4. Phase 1 & Phase 2a: Time to Response (TTR)

    TTR will be determined by investigator per RECIST v1.1 in non-PC/non-GBM participants, per RECIST v1.1 for soft tissue and PCWG3 criteria for bone metastases in PC participants, and per RANO 2.0 criteria in GBM participants

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  5. Phase 1 & Phase 2a: Progression Free Survival (PFS)

    PFS will be determined by investigator per RECIST v1.1 in non-PC/non-GBM participants, and per RANO 2.0 criteria in GBM participants

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  6. Phase 1 & Phase 2a: Radiographic Progression Free Survival (rPFS)

    rPFS will be determined by investigator per RECIST v1.1 for soft tissue and PCWG3 criteria for bone metastases in PC participants

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  7. Phase 1 & Phase 2a: Overall Survival (OS)

    OS is defined as the time from date of first dose to the date of death.

    Time frame: From date of first dose until the date of death or lost to follow up, approximately 1 year post-treatment

  8. Phase 2a: Prostate-specific antigen (PSA)

    Time to PSA progression, PSA50 response rate and PSA90 response rate, duration of PSA response in PC participants and the rate of PSA conversion to \<0.2 in CSPC.

    Time frame: From date of first dose until the date of first PSA progression, approximately 1 year post-treatment

  9. Phase 2a: CA-125 response rate

    CA-125 response assessed per GCIG criteria for ovarian cancer subjects

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  10. Phase 1 & Phase 2a: Pharmacokinetic-AUC

    Area under the concentration-time curve from time 0 to infinity of DB-1311/BNT324 ADC, total anti-B7-H3 antibody, and unconjugated P1021

    Time frame: within 8 cycles (each cycle is 21 days)

  11. Phase 1 & Phase 2a: Pharmacokinetic-Cmax

    Maximum observed plasma concentration (Cmax) of DB-1311/BNT324 ADC, total anti-B7-H3 antibody, and unconjugated P1021

    Time frame: within 8 cycles (each cycle is 21 days)

  12. Phase 1 & Phase 2a: Pharmacokinetic-Tmax

    Time to Cmax of DB-1311/BNT324 ADC, total anti-B7-H3 antibody, and unconjugated P1021

    Time frame: within 8 cycles (each cycle is 21 days)

  13. Phase 1 & Phase 2a: Pharmacokinetic-Cthrough

    Trough concentration

    Time frame: within 8 cycles (each cycle is 21 days)

  14. Phase 1 & 2a: Anti-drug antibody (ADA) prevalence

    Percentage of participants who are ADA positive at any point

    Time frame: Up to follow-up period, approximately 1 year post-treatment

  15. Phase 1 & 2a: ADA incidence

    Percentage of participants having treatment-emergent ADA

    Time frame: Up to follow-up period, approximately 1 year post-treatment

07

Study locations

107 of 107 sites recruiting
  • Research Site 111
    Tucson, Arizona 85711, United States
    Recruiting
  • Research Site 125
    Los Angeles, California 90033, United States
    Recruiting
  • Research Site 133
    Los Angeles, California 90067, United States
    Recruiting
  • Research Site 103
    Los Angeles, California 90095, United States
    Recruiting
  • Research Site 128
    Santa Monica, California 90403, United States
    Recruiting
  • Research Site 118
    Celebration, Florida 34747, United States
    Recruiting
  • Research Site 127
    Margate, Florida 33063, United States
    Recruiting
  • Research Site 137
    Orlando, Florida 32827, United States
    Recruiting
  • Research Site 101
    Plantation, Florida 33322, United States
    Recruiting
  • Research Site 109
    Tamarac, Florida 33321, United States
    Recruiting
  • Research Site 114
    Atlanta, Georgia 30318, United States
    Recruiting
  • Research Site 139
    Atlanta, Georgia 30322, United States
    Recruiting
  • Research Site 115
    Louisville, Kentucky 40202, United States
    Recruiting
  • Research Site 129
    Detroit, Michigan 48201, United States
    Recruiting
  • Research Site 121
    Saint Paul, Minnesota 55101, United States
    Recruiting
  • Research Site 110
    Las Vegas, Nevada 89169, United States
    Recruiting
  • Research Site 107
    New York, New York 10032, United States
    Recruiting
  • Research Site 138
    Canton, Ohio 44718, United States
    Recruiting
  • Research Site 113
    Cincinnati, Ohio 45267, United States
    Recruiting
  • Research Site 131
    Dayton, Ohio 45409, United States
    Recruiting
  • Research Site 123
    Charleston, South Carolina 29425, United States
    Recruiting
  • Research Site 108
    Greenville, South Carolina 29607, United States
    Recruiting
  • Research Site 136
    Nashville, Tennessee 37203, United States
    Recruiting
  • Research Site 135
    Austin, Texas 78731, United States
    Recruiting
  • Research Site 120
    Dallas, Texas 75390, United States
    Recruiting
  • Research Site 102
    Fairfax, Virginia 22031, United States
    Recruiting
  • Research Site 112
    Fairfax, Virginia 22031, United States
    Recruiting
  • Research Site 105
    Spokane, Washington 99208, United States
    Recruiting
  • Research Site 208
    Blacktown, New South Wales 2148, Australia
    Recruiting
  • Research Site 215
    Camperdown, New South Wales 2050, Australia
    Recruiting
  • Research Site 212
    Concord, New South Wales 2139, Australia
    Recruiting
  • Research Site 217
    New Lambton Heights, New South Wales 2305, Australia
    Recruiting
  • Research Site 201
    Sydney, New South Wales 2031, Australia
    Recruiting
  • Research Site 205
    Sydney, New South Wales 2109, Australia
    Recruiting
  • Research Site 206
    Sydney, New South Wales 2228, Australia
    Recruiting
  • Research Site 216
    Waratah, New South Wales 2298, Australia
    Recruiting
  • Research Site 209
    Birtinya, Queensland 4575, Australia
    Recruiting
  • Research Site 203
    Brisbane, Queensland 4102, Australia
    Recruiting
  • Research Site 210
    Gold Coast, Queensland 4224, Australia
    Recruiting
  • Research Site 202
    Nedlands, Western Australia 6009, Australia
    Recruiting
  • Research Site 207
    Nedlands, Western Australia 6009, Australia
    Recruiting
  • Research Site 319
    Hefei, Anhui 230031, China
    Recruiting
  • Research Site 365
    Beijing, Beijing Municipality 100034, China
    Recruiting
  • Research Site 310
    Beijing, Beijing Municipality 100142, China
    Recruiting
  • Research Site 337
    Beijing, Beijing Municipality 100142, China
    Recruiting
  • Research Site 327
    Chongqing, Chongqing Municipality 400030, China
    Recruiting
  • Research Site 345
    Chongqing, Chongqing Municipality 400072, China
    Recruiting
  • Research Site 353
    Chongqing, Chongqing Municipality 400072, China
    Recruiting
  • Research Site 356
    Chongqing, Chongqing Municipality 400072, China
    Recruiting
  • Research Site 313
    Fuzhou, Fujian 350001, China
    Recruiting
  • Research Site 314
    Guangzhou, Guangdong 510060, China
    Recruiting
  • Research Site 322
    Guangzhou, Guangdong 510060, China
    Recruiting
  • Research site 367
    Guangzhou, Guangdong 510120, China
    Recruiting
  • Research Site 346
    Guangzhou, Guangdong 510282, China
    Recruiting
  • Research Site 348
    Guangzhou, Guangdong 510300, China
    Recruiting
  • Research Site 350
    Guangzhou, Guangdong 510515, China
    Recruiting
  • Research Site 360
    Nanning, Guangxi 530021, China
    Recruiting
  • Research Site 334
    Baoding, Hebei 071030, China
    Recruiting
  • Research Site 315
    Harbin, Heilongjiang 150081, China
    Recruiting
  • Research Site 316
    Luoyang, Henan 450000, China
    Recruiting
  • Research Site 317
    Xinxiang, Henan 453100, China
    Recruiting
  • Research Site 306
    Zhengzhou, Henan 450000, China
    Recruiting
  • Research Site 304
    Zhengzhou, Henan 450052, China
    Recruiting
  • Research Site 321
    Wuhan, Hubei 430000, China
    Recruiting
  • Research Site 311
    Wuhan, Hubei 430030, China
    Recruiting
  • Research Site 309
    Changsha, Hunan 410031, China
    Recruiting
  • Research Site 323
    Changsha, Hunan 410031, China
    Recruiting
  • Research Site 344
    Nanjing, Jiangsu 210008, China
    Recruiting
  • Research Site 305
    Nanjing, Jiangsu 21000, China
    Recruiting
  • Research Site 307
    Ganzhou, Jiangxi 341000, China
    Recruiting
  • Research Site 349
    Nanchang, Jiangxi 330006, China
    Recruiting
  • Research Site 361
    Nanchang, Jiangxi 330029, China
    Recruiting
  • Research Site 328
    Changchun, Jilin 130000, China
    Recruiting
  • Research Site 301
    Changchun, Jilin 130012, China
    Recruiting
  • Research Site 320
    Shenyang, Liaoning 110000, China
    Recruiting
  • Research Site 352
    Shenyang, Liaoning 110042, China
    Recruiting
  • Research Site 363
    Nanjing, Nanjing 210006, China
    Recruiting
  • Research Site 340
    Jinan, Shandong 250013, China
    Recruiting
  • Research Site 308
    Jinan, Shandong 250117, China
    Recruiting
  • Research Site 333
    Linyi, Shandong 276000, China
    Recruiting
  • Research Site 302
    Linyi, Shandong 276034, China
    Recruiting
  • Research Site 335
    Shanghai, Shanghai Municipality 200030, China
    Recruiting
  • Research Site 326
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
  • Research Site 355
    Shanghai, Shanghai Municipality 200120, China
    Recruiting
  • Research Site 332
    Xi’an, Shanxi 710000, China
    Recruiting
  • Research Site 312
    Chengdu, Sichuan 610041, China
    Recruiting
  • Research Site 330
    Chengdu, Sichuan 610041, China
    Recruiting
  • Research Site 366
    Chengdu, Sichuan 610041, China
    Recruiting
  • Research Site 325
    Chengdu, Sichuan 610072, China
    Recruiting
  • Research Site 347
    Tianjin, Tianjin Municipality 300052, China
    Recruiting
  • Research Site 318
    Tianjin, Tianjin Municipality 300060, China
    Recruiting
  • Research site 368
    Tianjin, Tianjin Municipality 300300, China
    Recruiting
  • Research Site 324
    Hangzhou, Zhejiang 310014, China
    Recruiting
  • Research Site 329
    Hangzhou, Zhejiang 310016, China
    Recruiting
  • Research Site 331
    Hangzhou, Zhejiang 310022, China
    Recruiting
  • Research Site 359
    Hangzhou, Zhejiang 310022, China
    Recruiting
  • Research site 369
    Hangzhou, Zhejiang 310022, China
    Recruiting
  • Research Site 303
    Taizhou, Zhejiang 317099, China
    Recruiting
  • Research Site 408
    Kaohsiung City, 807377, Taiwan
    Recruiting
  • Research Site 405
    Kaohsiung City, 824005, Taiwan
    Recruiting

Showing the first 100 of 107 sites across 4 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Dec 2027, 52 months after the start.

Of 71 industry-sponsored phase 1/2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 74. This study's planned 52 months is close to that.

Counting every sponsor, half of 98 studies reached it within 54 months; a quarter within 44 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2023
First posted
Jun 22, 2023
StartActual
Aug 17, 2023
Primary completionEst.
Dec 2027
CompletionEst.
May 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: l•••@dualitybiologics.com · •••8730→n•••@dualitybiologics.com · •••8730; t•••@dualitybiologics.com→j•••@dualitybiologics.com. See the current contact
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Contact Study contact changed: l•••@dualitybiologics.com · •••8730→n•••@dualitybiologics.com · •••8730; t•••@dualitybiologics.com→j•••@dualitybiologics.com. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05914116
Lead sponsor
DualityBio Inc.
Collaborators
BioNTech SE
Responsible party
Sponsor
First posted
Jun 22, 2023
Start date
Aug 17, 2023
Primary completion
Dec 2027 (estimated)
Completion
May 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Nicole Huang
Contact
nicole.huang@dualitybiologics.com
86-21-26018730
Lily Hu
study director · DualityBio Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elfetabart Drozuntecan

Start the discussion